Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kobe Best Basal Insulin Study 2: Insulin degludec vs insulin glargine U300 in type 1 diabetes
jRCTs051180138Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of insulin degludec and insulin glargine U300 in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Day-to-day variability of fasting plasma glucose (primary). Started Jun 2018; status: completed.
02
Drugs
insulin degludecinsulin glargine U300
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on jRCTs051180138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180138.